Merck, Eisai announce follow-up data on KEYTRUDA plus LENVIMA

Merck (MRK) and Eisai (ESAIY) announced long-term follow-up data continued to show durable benefit of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor, TKI, discovered by Eisai, compared to chemotherapy for patients with advanced endometrial carcinoma following at least one prior platinum-based regimen in any setting. The findings, based on five years of follow-up from the Phase 3 KEYNOTE-775/Study 309 trial evaluating KEYTRUDA plus LENVIMA versus chemotherapy, for these patients with advanced endometrial carcinoma are being presented during a poster session at the European Society for Medical Oncology, ESMO, Congress 2025 in Berlin, Germany. At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival rate for these patients with mismatch repair proficient advanced endometrial carcinoma versus 7.3% for chemotherapy alone in the pivotal Phase 3 KEYNOTE-775/Study 309 trial. Five-year OS results in the pMMR subgroup were consistent with the all-comers study population, which demonstrated an OS rate of 19.9% for KEYTRUDA plus LENVIMA versus 7.7% for chemotherapy.